JP2018174946A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018174946A5 JP2018174946A5 JP2018156070A JP2018156070A JP2018174946A5 JP 2018174946 A5 JP2018174946 A5 JP 2018174946A5 JP 2018156070 A JP2018156070 A JP 2018156070A JP 2018156070 A JP2018156070 A JP 2018156070A JP 2018174946 A5 JP2018174946 A5 JP 2018174946A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- protein
- hla
- cells
- hla class
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161477474P | 2011-04-20 | 2011-04-20 | |
| US61/477,474 | 2011-04-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506508A Division JP2014513948A (ja) | 2011-04-20 | 2012-04-18 | β２ミクログロブリン欠損細胞 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020166783A Division JP7260182B2 (ja) | 2011-04-20 | 2020-10-01 | β２ミクログロブリン欠損細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018174946A JP2018174946A (ja) | 2018-11-15 |
| JP2018174946A5 true JP2018174946A5 (enExample) | 2019-06-20 |
Family
ID=46051930
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506508A Pending JP2014513948A (ja) | 2011-04-20 | 2012-04-18 | β２ミクログロブリン欠損細胞 |
| JP2018156070A Pending JP2018174946A (ja) | 2011-04-20 | 2018-08-23 | β２ミクログロブリン欠損細胞 |
| JP2020166783A Active JP7260182B2 (ja) | 2011-04-20 | 2020-10-01 | β２ミクログロブリン欠損細胞 |
| JP2023054810A Active JP7586528B2 (ja) | 2011-04-20 | 2023-03-30 | β２ミクログロブリン欠損細胞 |
| JP2024190215A Pending JP2025010296A (ja) | 2011-04-20 | 2024-10-30 | β２ミクログロブリン欠損細胞 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506508A Pending JP2014513948A (ja) | 2011-04-20 | 2012-04-18 | β２ミクログロブリン欠損細胞 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020166783A Active JP7260182B2 (ja) | 2011-04-20 | 2020-10-01 | β２ミクログロブリン欠損細胞 |
| JP2023054810A Active JP7586528B2 (ja) | 2011-04-20 | 2023-03-30 | β２ミクログロブリン欠損細胞 |
| JP2024190215A Pending JP2025010296A (ja) | 2011-04-20 | 2024-10-30 | β２ミクログロブリン欠損細胞 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20140134195A1 (enExample) |
| EP (1) | EP2699593B2 (enExample) |
| JP (5) | JP2014513948A (enExample) |
| CA (2) | CA3205636A1 (enExample) |
| DK (1) | DK2699593T4 (enExample) |
| WO (1) | WO2012145384A1 (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014513948A (ja) * | 2011-04-20 | 2014-06-19 | ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーション | β２ミクログロブリン欠損細胞 |
| PL2838548T3 (pl) * | 2012-04-17 | 2024-02-05 | University Of Washington Through Its Center For Commercialization | Komórki z niedoborem hla klasy ii, komórki z niedoborem hla klasy i, zdolne do ekspresji białek hla klasy ii i ich zastosowania |
| CN114558032B (zh) * | 2012-12-21 | 2025-07-29 | 安斯泰来再生医药协会 | 由多能干细胞制备血小板的方法及其组合物 |
| CA2913854A1 (en) * | 2013-06-03 | 2014-12-11 | Theravectys | Lentiviral vectors containing an mhc class i, mhc class ii, or beta-2 microglobulin upstream promoter sequence |
| AU2015216875B2 (en) | 2014-02-14 | 2021-02-25 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| MX373460B (es) | 2014-03-11 | 2020-04-07 | Cellectis | Metodo para generar celulas t compatibles para el trasplante alogenico. |
| GB201412494D0 (en) | 2014-07-14 | 2014-08-27 | Ospedale San Raffaele And Fond Telethon | Vector production |
| KR20170075013A (ko) | 2014-10-31 | 2017-06-30 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Cart 세포에서 유전자 발현의 변경 및 그의 용도 |
| EP3215623A4 (en) | 2014-11-06 | 2018-09-26 | President and Fellows of Harvard College | Cells lacking b2m surface expression and methods for allogeneic administration of such cells |
| EP3229586B1 (en) | 2014-12-10 | 2025-07-30 | Regents of the University of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| CA2988854A1 (en) | 2015-05-08 | 2016-11-17 | President And Fellows Of Harvard College | Universal donor stem cells and related methods |
| EP3519562A4 (en) * | 2016-09-29 | 2020-03-25 | Nantkwest, Inc. | NK-92 HLA CLASS I DEFICIENT CELLS WITH REDUCED IMMUNOGENICITY |
| KR20250007053A (ko) * | 2017-05-23 | 2025-01-13 | 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 | 타겟화된 치료학적 면역조절을 위한 mhc 클래스 ib 분자와 펩타이드의 조합 |
| US10391156B2 (en) * | 2017-07-12 | 2019-08-27 | Viacyte, Inc. | University donor cells and related methods |
| TW201920249A (zh) | 2017-09-07 | 2019-06-01 | 美商信號生物製藥公司 | 具有結合位點之t細胞調節多聚體多肽及其使用方法 |
| EP3684919A1 (en) * | 2017-10-19 | 2020-07-29 | Cellectis | Targeted gene integration of nk inhibitors genes for improved immune cells therapy |
| EP3727467A4 (en) * | 2017-12-22 | 2021-12-01 | Centivax, Inc. | MAJOR HISTOCOMPATIBILITY COMPLEX (CMH) COMPOSITIONS AND CORRESPONDING PROCEDURES FOR USE |
| EP3754018A4 (en) | 2018-02-16 | 2021-11-24 | Kyoto University | METHOD OF MANUFACTURING A WEAK ANTIGENT CELL |
| JP2021513839A (ja) * | 2018-02-16 | 2021-06-03 | カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ | 改変された多能性幹細胞並びに製造方法及び使用方法 |
| KR102304549B1 (ko) * | 2018-05-30 | 2021-09-27 | 주식회사 강스템바이오텍 | Hla 유전자가 제거된 인간 유도만능줄기세포 유래 중간엽줄기세포 및 그의 제조 방법 |
| CN112955542A (zh) * | 2018-07-13 | 2021-06-11 | L·杰罗姆罗 | 非免疫原性工程化组织及其生产方法和用途 |
| IL280610B2 (en) | 2018-08-31 | 2024-08-01 | Wisconsin Alumni Res Found | Fabrication of vascular grafts seeded with arterial endothelial cells |
| AU2019336221B2 (en) | 2018-09-07 | 2025-05-15 | Wisconsin Alumni Research Foundation | Generation of hematopoietic progenitor cells from human pluripotent stem cells |
| US10724052B2 (en) | 2018-09-07 | 2020-07-28 | Crispr Therapeutics Ag | Universal donor cells |
| WO2020067993A1 (en) * | 2018-09-26 | 2020-04-02 | National University Of Singapore | Engineered human mesenchymal stromal cells with low immunogenicity, methods and kits of generating the same |
| US11793834B2 (en) | 2018-12-12 | 2023-10-24 | Kite Pharma, Inc. | Chimeric antigen and T cell receptors and methods of use |
| SG11202108346WA (en) | 2019-02-13 | 2021-08-30 | Beam Therapeutics Inc | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| WO2020206248A1 (en) | 2019-04-03 | 2020-10-08 | Precision Biosciences, Inc. | Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) |
| TW202115245A (zh) | 2019-06-27 | 2021-04-16 | 丹麥商諾佛 儂迪克股份有限公司 | 安全免疫隱形細胞 |
| AU2020340622A1 (en) | 2019-09-05 | 2022-03-03 | Crispr Therapeutics Ag | Universal donor cells |
| US11118195B2 (en) | 2019-09-05 | 2021-09-14 | Crispr Therapeutics Ag | Universal donor cells |
| CN115279398B (zh) | 2019-09-27 | 2025-07-04 | 比姆医疗股份有限公司 | 治疗液态癌症的组合物和方法 |
| AU2020370254B2 (en) * | 2019-10-22 | 2026-04-23 | The Trustees Of Columbia University In The City Of New York | Transgenic swine, methods of making and uses thereof, and methods of making human immune system mice |
| JP7618337B2 (ja) * | 2020-01-10 | 2025-01-21 | エルジー・ケム・リミテッド | Ｍｈｃおよび腫瘍抗原を同時発現する抗原提示細胞を含む組成物およびこれを用いた癌治療 |
| MX2022011245A (es) | 2020-03-11 | 2023-01-11 | Bit Bio Ltd | Método de generación de células hepáticas. |
| JP2023525049A (ja) * | 2020-05-08 | 2023-06-14 | シアトル・チルドレンズ・ホスピタル・ドゥーイング／ビジネス／アズ・シアトル・チルドレンズ・リサーチ・インスティテュート | ナチュラルキラー細胞を標的とするキメラ抗原受容体（ｃａｒ） |
| WO2021231712A1 (en) * | 2020-05-15 | 2021-11-18 | Rxcell Inc. | Hypoimmunogenic cells and uses thereof in immune responses |
| WO2021242935A1 (en) * | 2020-05-26 | 2021-12-02 | Cue Biopharma, Inc. | Antigen presenting polypeptide complexes and methods of use thereof |
| WO2022038411A1 (en) | 2020-08-19 | 2022-02-24 | Astellas Pharma, Inc. | Human non-naturally occurring modified fc region of igg specifically binding to non-naturally occurring modified fc receptor |
| EP4200023A4 (en) * | 2020-08-23 | 2024-10-30 | Applied StemCell, Inc. | Hla-f-modified cells and methods |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| TW202237827A (zh) | 2020-12-03 | 2022-10-01 | 美商世紀治療股份有限公司 | 經基因工程改造之細胞及其用途 |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| WO2022129472A1 (en) | 2020-12-18 | 2022-06-23 | Novo Nordisk A/S | Safe immuno-stealth cells |
| WO2022136215A1 (en) | 2020-12-21 | 2022-06-30 | Novo Nordisk A/S | Safe immuno-stealth cells |
| US11473060B2 (en) | 2020-12-30 | 2022-10-18 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into NK cells |
| KR20230146007A (ko) | 2020-12-31 | 2023-10-18 | 크리스퍼 테라퓨틱스 아게 | 범용 공여자 세포 |
| TW202246494A (zh) * | 2021-01-26 | 2022-12-01 | 美商艾姆比斯藥品公司 | 基因改造肝細胞群 |
| WO2022191216A1 (ja) | 2021-03-09 | 2022-09-15 | 国立研究開発法人理化学研究所 | 低免疫原性網膜色素上皮細胞の製造方法 |
| US20240200031A1 (en) * | 2021-04-12 | 2024-06-20 | Memorial Sloan Kettering Cancer Center | Engineered hla molecules useful for t cell and nk cell activation and expansion |
| CA3216719A1 (en) | 2021-05-03 | 2022-11-10 | Astellas Institute For Regenerative Medicine | Methods of generating mature corneal endothelial cells |
| TW202309268A (zh) | 2021-05-07 | 2023-03-01 | 安斯泰來再生醫藥協會 | 產生成熟肝細胞的方法 |
| AU2022299551A1 (en) * | 2021-06-23 | 2024-01-18 | Editas Medicine, Inc. | Engineered cells for therapy |
| EP4407028A4 (en) | 2021-09-24 | 2025-08-06 | Cira Found | METHOD FOR PRODUCING MODIFIED HUMAN INDUCED PLURIPOTENT STEM CELLS |
| WO2023069480A1 (en) * | 2021-10-20 | 2023-04-27 | Vascugen, Inc. | Hypoimmune vasculogenic cells |
| AU2023246279A1 (en) | 2022-04-01 | 2024-11-14 | LogoMix, Inc. | Cell suitable for gene engineering, cell engineering and cellular medicine, and method for producing same |
| US20260002124A1 (en) | 2022-07-01 | 2026-01-01 | Novo Nordisk A/S | Enhancing neuronal differentiation of ventral midbrain neural progenitor cells |
| TW202417614A (zh) | 2022-08-23 | 2024-05-01 | 安斯泰來再生醫藥協會 | 用於治療眼部病症的感光救援細胞（prc）組成物及方法 |
| EP4577223A2 (en) * | 2022-08-26 | 2025-07-02 | Beam Therapeutics Inc. | Modified allogeneic cells and methods and compositions for the preparation thereof |
| EP4610277A1 (en) | 2022-10-25 | 2025-09-03 | Daiichi Sankyo Company, Limited | Method for avoiding immune rejection using agonist for inhibitory kir |
| EP4619033A1 (en) * | 2022-11-17 | 2025-09-24 | The Trustees of Indiana University | Novel biomarker and target for treating pulmonary hypertension |
| CN120898000A (zh) | 2023-01-13 | 2025-11-04 | 拉维洛克治疗有限责任公司 | 新的多核苷酸、细胞和方法 |
| EP4735585A1 (en) | 2023-06-30 | 2026-05-06 | Novo Nordisk A/S | Enhancing neuronal differentiation of neural progenitor cells |
| CN121941763A (zh) * | 2023-09-29 | 2026-04-28 | 味之素株式会社 | Hla基因修饰细胞 |
| GB202316281D0 (en) * | 2023-10-24 | 2023-12-06 | Replay Holdings Inc | Methods and compositions for modulating immune cell activity in cellular therapy |
| WO2025235955A1 (en) * | 2024-05-10 | 2025-11-13 | Bluerock Therapeutics Lp | Genetically engineered cells for enhanced immune evasion and methods thereof |
| WO2026035951A2 (en) | 2024-08-07 | 2026-02-12 | Legend Biotech Ireland Limited | Cells overexpressing cd43 and methods of use thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US5574205A (en) * | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| WO1991010470A1 (en) | 1990-01-08 | 1991-07-25 | Brown University Research Foundation | Devices and methods for enhanced delivery of active factors |
| WO1992009688A1 (en) | 1990-11-21 | 1992-06-11 | Massachusetts Institute Of Technology | MICE HAVING β2 MICROGLOBULIN GENE DISRUPTION |
| AU2661692A (en) | 1991-09-19 | 1993-04-27 | President And Fellows Of Harvard College | Transgenic mhc class i and class ii antigen-deficient mammals |
| CA2110946A1 (en) | 1992-12-09 | 1994-06-10 | Elazar Rabbani | Induction of immunocompatibility by nucleic acid |
| US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
| US5869270A (en) | 1996-01-31 | 1999-02-09 | Sunol Molecular Corporation | Single chain MHC complexes and uses thereof |
| EP0972039A1 (en) | 1997-03-25 | 2000-01-19 | Morphogenesis, Inc. | Universal stem cells |
| US6420518B1 (en) * | 1997-04-04 | 2002-07-16 | Genetech, Inc. | Insulin-like growth factor agonist molecules |
| EP0995798A1 (en) | 1998-10-24 | 2000-04-26 | Novimmune Sa | Transcription factor of MHC class II genes, substances capable of inhibiting this new transcription factor and medical uses of these substances |
| IL151860A0 (en) | 2000-03-27 | 2003-04-10 | Technion Res & Dev Foundation | Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same |
| DE10132502A1 (de) | 2001-07-05 | 2003-01-23 | Gsf Forschungszentrum Umwelt | Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen |
| US20040225112A1 (en) | 2003-05-06 | 2004-11-11 | Crew Mark D. | Genes encoding single chain human leukocyte antigen E (HLA-E) proteins to prevent natural killer cell-mediated cytotoxicity |
| FR2856599A1 (fr) | 2003-06-30 | 2004-12-31 | Commissariat Energie Atomique | Utilisation de compositions contenant une forme soluble d'hla-g dans le traitement de pathologies du sang. |
| SG146691A1 (en) * | 2003-10-08 | 2008-10-30 | Vet Stem Inc | Methods of preparing and using stem cell compositions and kits comprising the same |
| WO2007091078A2 (en) | 2006-02-10 | 2007-08-16 | Axordia Limited | Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g |
| US8105831B2 (en) | 2007-03-09 | 2012-01-31 | University Of Washington | Parvoviral production of HLA homozygous cells |
| WO2008124142A1 (en) | 2007-04-06 | 2008-10-16 | International Stem Cell Corporation | Patient-specific stem cell lines derived from human parthenogenetic blastocysts |
| JP5267969B2 (ja) * | 2007-12-04 | 2013-08-21 | 学校法人慶應義塾 | 癌ワクチン |
| EP2184297A1 (en) * | 2008-11-07 | 2010-05-12 | Hla-G Technologies | HLA-G polypeptides and pharmaceutical uses thereof |
| CA3157027A1 (en) | 2010-07-21 | 2012-01-26 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a t-cell receptor gene |
| JP2014513948A (ja) * | 2011-04-20 | 2014-06-19 | ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーション | β２ミクログロブリン欠損細胞 |
| KR102055438B1 (ko) | 2012-07-31 | 2019-12-19 | 에이지엑스 쎄라퓨틱스, 인크. | Hla g-변형된 세포 및 방법 |
-
2012
- 2012-04-18 JP JP2014506508A patent/JP2014513948A/ja active Pending
- 2012-04-18 DK DK12720040.0T patent/DK2699593T4/da active
- 2012-04-18 CA CA3205636A patent/CA3205636A1/en active Pending
- 2012-04-18 CA CA2833173A patent/CA2833173C/en active Active
- 2012-04-18 US US14/111,837 patent/US20140134195A1/en not_active Abandoned
- 2012-04-18 WO PCT/US2012/034051 patent/WO2012145384A1/en not_active Ceased
- 2012-04-18 EP EP12720040.0A patent/EP2699593B2/en active Active
-
2018
- 2018-08-23 JP JP2018156070A patent/JP2018174946A/ja active Pending
-
2019
- 2019-07-10 US US16/507,589 patent/US11813318B2/en active Active
-
2020
- 2020-10-01 JP JP2020166783A patent/JP7260182B2/ja active Active
-
2023
- 2023-03-30 JP JP2023054810A patent/JP7586528B2/ja active Active
- 2023-10-12 US US18/485,536 patent/US20240207378A1/en active Pending
-
2024
- 2024-10-30 JP JP2024190215A patent/JP2025010296A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014513948A5 (enExample) | ||
| JP2024144548A5 (enExample) | ||
| Salvato | The arenaviridae | |
| JP2022162047A5 (enExample) | ||
| Baghaei et al. | Isolation, differentiation, and characterization of mesenchymal stem cells from human bone marrow | |
| JP6770989B2 (ja) | 標的細胞を可逆的に染色する方法 | |
| Ratajczak et al. | A novel view of the adult stem cell compartment from the perspective of a quiescent population of very small embryonic-like stem cells | |
| Bachem et al. | Superior antigen cross-presentation and XCR1 expression define human CD11c+ CD141+ cells as homologues of mouse CD8+ dendritic cells | |
| Kocaoemer et al. | Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue | |
| Alves et al. | Serial progression of cortical and medullary thymic epithelial microenvironments | |
| Correia et al. | IL-15 induces CD8+ T cells to acquire functional NK receptors capable of modulating cytotoxicity and cytokine secretion | |
| Liu et al. | Low immunogenicity of neural progenitor cells differentiated from induced pluripotent stem cells derived from less immunogenic somatic cells | |
| JP2019050826A (ja) | 自己癌抗原特異的ｃｄ８＋ｔ細胞の分離及び増殖方法 | |
| JP2012528599A5 (enExample) | ||
| Körner et al. | Increased frequency and function of KIR2DL1–3+ NK cells in primary HIV‐1 infection are determined by HLA‐C group haplotypes | |
| HRP20160915T1 (hr) | Nova imunoterapija protiv nekoliko tumora uključujući neuronske tumore i tumore mozga | |
| JP2014520551A5 (enExample) | ||
| HRP20210076T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma ezofagusa i drugih karcinoma | |
| CA2649874C (en) | Immune privileged and modulatory progenitor cells | |
| Stockinger et al. | CD4 T-cell memory | |
| Sun et al. | Study of the protective effect on damaged intestinal epithelial cells of rat multilineage‐differentiating stress‐enduring (Muse) cells | |
| Daniel et al. | CD4+ CD25+ Foxp3+ IFNγ+ CD178+ human induced Treg (iTreg) contribute to suppression of alloresponses by apoptosis of responder cells | |
| Jung et al. | KIR3DS1 directs NK cell–mediated protection against human adenovirus infections | |
| CN104946590A (zh) | 成人骨髓中Muse细胞诱导为神经前体细胞的方法 | |
| Poole et al. | An iPSC-derived myeloid lineage model of herpes virus latency and reactivation |